The 2019 CSCCP conference was held in full swing in Shenzhen from May 9 to 12, 2019. Although we were not able to attend the conference in person as we wished, relying on the online platform, I led the department colposcopists could still learn advanced knowledge and experience of cervical disease at home and abroad through live streaming or return videos for physical and mental pleasure. Cervical cancer is a major killer of women’s health and seriously affects countless families, making it a serious public health issue. However, after extensive scientific research, cervical cancer is the only human tumor that has a clear cause and a preventive vaccine. The World Health Organization (WHO) has long proposed prevention and control measures for cervical cancer: first, cervical cancer vaccine is the primary prevention of cervical cancer; second, cervical cancer screening to identify precancerous lesions is the secondary prevention; third, early detection, diagnosis and treatment of cervical cancer to improve 5-year survival rate and reduce mortality is the tertiary prevention of cervical cancer. In May 2018 TedrosAdhanomGhebreyesus, director general of the World Health Organization (WHO), announced a call for coordinated action to eliminate cervical cancer in public health health issues and plans to submit a resolution on a global strategy for cervical cancer elimination at the World Health Assembly in 2020. By elimination (elimination), we mean controlling cervical cancer at the threshold of rare cancers (4/100,000 new cases per year). Currently, there are 500,000 new cases per year worldwide and 130,000 per year in China. WHO proposes to eliminate cervical cancer aiming to control the incidence of cervical cancer to the level of rare tumor (4/100,000) in 50 years (2069), not to eliminate it. Although China is currently the second largest economy in the world, our basic national condition is a large population with a weak base and uneven regional development. This is coupled with the fact that the cervical cancer vaccine is resource constrained and expensive. It is really a long way to go to achieve this goal! It requires the efforts of the whole society to strive for 90% of adolescents under 15 years of age to participate in HPV preventive vaccination in the near future (2020-2030), active participation of older age groups (35-45 years old) in cervical screening, screening coverage of more than 70%, and every doctor remembering to remind patients and friends around them to participate in screening and preventive vaccination. I was thrilled to learn that our regional CDC had begun purchasing the vaccine. We counted appointments for cervical cancer vaccination in and around our units for people of appropriate age. At the grassroots level, I strongly urge the procurement of the 2-valent vaccine because the 2-valent vaccine has wide age coverage (9 to 26 years old), cross-protection i.e., in addition to being effective against HPV types 16 and 18, it has cross-protection against types 31, 33, and 35, and is relatively the cheapest, so the 2-valent vaccine is the most cost-effective. The 4-valent vaccine covers ages 20 to 45 and protects against HPV types 16, 18, 6 and 11. 9-valent vaccine covers ages 16 to 26 in China. Therefore, we need to rely on the contribution of the 2-valent vaccine to achieve 90% of cervical cancer vaccination under 15 years of age by 2030. Due to the lack of vaccine resources, we also call for the limited vaccine resources to be used on the cutting edge, that is, the “children”, and those who have already given birth, especially the older women over 40 years old, should not compete with the “flowers and bones” for resources. Just use the money for vaccinations to get screened on time. That’s what our cervical disease doctors always say: screening for moms, vaccination for daughters. With vaccination and combined TCT+hpv screening for cervical cancer, 90% of cervical cancers can be killed in the cradle after several years of effort. And screening for abnormalities gives precise interpretation and leads to timely intervention or treatment for more than 90% of patients. This will reduce the occurrence of advanced cervical cancer and reach the goal of reducing cervical cancer mortality by 30%. Only through these measures and methods, which include 90% vaccination rate for younger women, 70% screening rate for older women, 90% intervention rate for screening abnormalities, and 30% reduction in cervical cancer mortality in the last 10 years, can we finally achieve the goal of eliminating cervical cancer in 50 years, i.e. 2069, which means that cervical cancer will become a rare cancer. As a colposcopy center in our region, we are proud that each of us colposcopists are working towards this great goal of the WHO.